NEW YORK (GenomeWeb News) — Contract research company BioFocus DPI said today that it has installed a Waters Xevo TQ Mass Spectrometer for use in its drug metabolite discovery services for pharmaceutical clients.

Using the Xevo alongside Waters' UltraPerformance liquid chromatography technology will increase the lab’s throughput and "allows more accurate measurements to both quantify and confirm the identity of metabolites in a wide range of biological fluids and tissues," enabling an increased likelihood of metabolite detection, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.